The present invention provides rebamipide for use in a method of prevention and/or treatment of celiac disease, particularly in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Furthermore, it provides rebamipide for use in a method of inhibiting a gluten-induced increase in intestinal permeability.
The present invention relates to the use of rebamipide in a method of prevention and/or treatment of arterial stiffness and associated diseases, such as hypertension, heart failure, myocardial infarction, stroke, peripheral arterial disease, renal failure, and chronic kidney disease. Rebamipide may also be used in a method of increasing arterial elasticity.
The present invention relates to rebamipide for use in a method of prophylaxis and/or treatment of cancer in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability, e.g. due to family anamnesis or due to exposure to conditions or substances inducing increased intestinal permeability.
The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.
A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
A61K 31/655 - Composés azoïques(-N=N-), diazoïques (=N2), azoxy (N-O-N ou N(=O)-N), azido (-N3) ou diazoamino (-N=N-N)
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
The present invention provides rebamipide for use in a method of prevention and/or treatment of a synucleinopathy, in particular of Parkinson's disease. In particular, rebamipide is used in prevention and/or treatment of a synucleinopathy in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.
The present invention relates to the use of rebamipide in a method of prevention and/or treatment of arterial stiffness and associated diseases, such as hypertension, heart failure, myocardial infarction, stroke, peripheral arterial disease, renal failure, and chronic kidney disease. Rebamipide may also be used in a method of increasing arterial elasticity.
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The present invention relates to the use of rebamipide in a method of prevention and/or treatment of arterial stiffness and associated diseases, such as hypertension, heart failure, myocardial infarction, stroke, peripheral arterial disease, renal failure, and chronic kidney disease. Rebamipide may also be used in a method of increasing arterial elasticity.
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The present invention relates to rebamipide for use in a method of prophylaxis and/or treatment of cancer in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability, e.g. due to family anamnesis or due to exposure to conditions or substances inducing increased intestinal permeability.
The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
10.
REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE
: The present invention provides rebamipide for use in a method of prevention and/or treatment of celiac disease, particularly in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Furthermore, it provides rebamipide for use in a method of inhibiting a gluten-induced increase in intestinal permeability.
: The present invention provides rebamipide for use in a method of prevention and/or treatment of celiac disease, particularly in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability. Furthermore, it provides rebamipide for use in a method of inhibiting a gluten-induced increase in intestinal permeability.
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
12.
REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER
The present invention relates to rebamipide for use in a method of prophylaxis and/or treatment of cancer in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability, e.g. due to family anamnesis or due to exposure to conditions or substances inducing increased intestinal permeability.
The present invention provides rebamipide for use in a method of prevention and/or treatment of Crohn's disease. In particular, rebamipide is used in prevention and/or treatment of Crohn's disease in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
14.
REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF SYNUCLEINOPATHIES
The present invention provides rebamipide for use in a method of prevention and/or treatment of a synucleinopathy, in particular of Parkinson´s disease. In particular, rebamipide is used in prevention and/or treatment of a synucleinopathy in a person suffering from increased intestinal permeability or in a person who is at risk of increased intestinal permeability.
brevets
